<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.37161.002</object-id><label>Table 1.</label><caption><title>Competitive inhibitors of estrogen receptor alpha.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Antiestrogen</th><th>Class</th><th>Approved clinical indications</th></tr></thead><tbody><tr><td> <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-37161-inf1-v2"/><break/>4-Hydroxytamoxifen (4-OHT)</td><td>SERM</td><td>&#8226; Adjuvant treatment for ER&#160;+&#160;breast cancers (<xref ref-type="bibr" rid="bib9">Early Breast Cancer Trialists' Collaborative Group., 1998</xref>). <break/>&#8226; Metastatic Breast Cancer (<xref ref-type="bibr" rid="bib30">Lipton, 1982</xref>). <break/>&#8226; Ductal Carcinoma in Situ (<xref ref-type="bibr" rid="bib1">Allred et al., 2012</xref>). <break/>&#8226; Reduction in Breast Cancer Incidence in High Risk Women (<xref ref-type="bibr" rid="bib51">Visvanathan, 2009</xref>).</td></tr><tr><td> <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-37161-inf2-v2"/><break/>Raloxifene (RAL)</td><td>SERM</td><td>&#8226; Osteoporosis in postmenopausal women (<xref ref-type="bibr" rid="bib32">Messalli and Scaffa, 2010</xref>). <break/>&#8226; Reduction in Breast Cancer Incidence in High Risk Women(<xref ref-type="bibr" rid="bib4">Cauley et al., 2001</xref>).</td></tr><tr><td> <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-37161-inf3-v2"/><break/>Fulvestrant (FULV)</td><td>SERD</td><td>&#8226; First-line therapy for metastatic breast cancer (<xref ref-type="bibr" rid="bib18">Howell et al., 2004</xref>). <break/>&#8226; Postmenopausal women with progressive breast cancer following other antiestrogen therapy (<xref ref-type="bibr" rid="bib36">Osborne et al., 2002</xref>; <xref ref-type="bibr" rid="bib17">Howell et al., 2002</xref>).</td></tr><tr><td> <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-37161-inf4-v2"/><break/>Bazedoxifene (BZA)</td><td>SERM/SERD</td><td>&#8226; In combination with conjugated equine estrogens (DUAVEE) to prevent postmenopausal osteoporosis (<xref ref-type="bibr" rid="bib46">Tikoo and Gupta, 2015</xref>).</td></tr></tbody></table></table-wrap>